CMAB Biopharma

13 articles about CMAB Biopharma

• CMAB Biopharma Congratulates Partner Junshi Biosciences on NMPA Acceptance of Application for a Clinical Trial of its PD-1/TGF-β Bifunctional Fusion Protein

  3/8/2021

  Recently, CMAB Biopharma Inc's partner Shanghai Junshi Biosciences Co., Ltd., announced that a clinical trial application for its PD-1/TGF-β bifunctional fusion protein JS201 injection has been accepted by National Medical Products Administration.

• CMAB Biopharma Congratulates Partner Innovent Biologics on FDA Clearance of IND Application of its COVID-19 Antibody Project

  3/3/2021

  CMAB Biopharma Inc congratulates its partner Innovent Biologics, Inc on the U.S. Food and Drug Administration clearance of an Investigational New Drug application for its antibody candidate which targets the COVID-19 virus, an independently-developed project by Innovent.

• CMAB Biopharma Congratulates QureBio on FDA Clearance of IND Application for Claudin18.2/PD-L1 Bispecific Antibody

  3/2/2021

  Recently, CMAB Biopharma Inc's partner QureBio Ltd has announced its innovative drug Q-1802 received United States Food and Drug Administration clearance for an Investigational New Drug application.

• CMAB Biopharma and Laekna Therapeutics Enter Strategic Agreement for LAE005 Global Development and Commercialization Partnership

  9/10/2020

  CMAB Biopharma (Suzhou) Inc. ("CMAB"), and Laekna Therapeutics Shanghai Co., Ltd. ("Laekna Therapeutics"), today announced a strategic collaboration agreement in Suzhou BioBAY for speedup of Immune Checkpoint Inhibitor (ICI) drug candidate to the clinical trial and future commercialization.

• CMAB Appoints Ms. Maggie Chen as Chief Financial Officer

  8/7/2020

  CMAB Biopharma Inc., a dedicated biologics contract manufacturing and development organization, announced the appointment of Ms. Maggie Chen as the chief financial officer.

• CMAB Biopharma's development and manufacturing platform successfully completes Q-1802 bispecific antibody project for QureBio within 9 months

  5/13/2020

  CMAB completed a full scope development and manufacturing project for Q-1802 in 9 months for dual IND filing in China and the US Completion of the project demonstrates the significant speed to clinic achievable with CMAB's fully integrated development and manufacturing platform QureBio's bispecific antibody Q-1802 will enter clinical trials to assess treatment of solid tumors s

• CMAB Biopharma Appoints Mr. Ye Shi as Head of Quality

  4/3/2020

  CMAB Biopharma Inc., a dedicated biologics contract manufacturing and development organization, announced the appointment of Mr. Ye Shi as the Head of Quality.

• CMAB Biopharma Resumes Full-Scale Operation Following the Coronavirus Disease 2019 (COVID-19) Outbreak

  3/23/2020

  CMAB Biopharma Inc., has continued to monitor the development of the COVID-19 pandemic and has taken proactive measures to primarily protect the health of our employees worldwide.

• CMAB Biopharma and Fapon Biopharma Sign Agreement to Develop and Manufacture a Biologic Oncology Asset

  12/2/2019

  The newly founded relationship will combine the research and development ingenuity of Fapon Biopharma with the state-of-art biologics manufacturing services offered by CMAB

• CMAB Biopharma and BJ Bioscience Establish an Exclusive Strategic Partnership

  10/11/2019

  The new partnership will combine the research and development ingenuity of BJ Bioscience with the state-of-art biologics manufacturing set up of CMAB

• CMAB Biopharma Receives Positive Opinion Following External Quality Audit

  9/5/2019

  CMAB Biopharma (Suzhou) Inc. announced a positive opinion in an external European quality audit conducted by Parexel International Co.

• CMAB Biopharma Announces Dr. Wang Yongzhong as CEO to Strengthen Leadership and Continue Business Expansion

  5/20/2019

  CMAB Biopharma Ltd. has announced the appointment of Dr. Wang Yongzhong as its CEO.

• CMAB Closes $38M Series A Financing Round

  1/3/2018

  The company will provide services for development of manufacturing processes, analytical methods, formulation, and manufacture of biologic drug substances and drug products.